CD274 and esophageal squamous cell carcinoma: Pembrolizumab–chemotherapy was superior to placebo–﻿chemotherapy for progression-free survival (PFS) (P < 0.0001) in the total population and in patients with ESCC and PD-L1 CPS ≥ 10.